Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058370 · ClinicalTrials.gov registry record · NA
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
A NA study of Brain and Central Nervous System Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 2
- Study locations
NCT00058370: Completed NA study of Brain and Central Nervous System Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00058370 is a NA study of Brain and Central Nervous System Tumors that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058370, a NA study of Brain and Central Nervous System Tumors, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Radioimmunotherapy uses radiolabeled monoclonal antibodies to locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining intrathecal radioimmunotherapy and radiation therapy with combination chemotherapy may kill any tumor cells remaining after surgery. PURPOSE: Phase II trial to study the effectiveness of combining intrathecal radioimmunotherapy and radiation therapy with combination chemotherapy in treating patients who have undergone surgery for medulloblastoma.
Conditions Studied
Interventions
- DRUG cisplatin
- PROCEDURE adjuvant therapy
- DRUG vincristine sulfate
- DRUG lomustine
- RADIATION iodine I 131 monoclonal antibody 3F8
Study Locations (2)
New York
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2003-02 |
| Est. Completion | 2019-06 |
| Phase | NA |
What the finished NCT00058370 record still lists
NCT00058370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00058370 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00058370 about?
NCT00058370 is a clinical study titled "Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma". RATIONALE: Radioimmunotherapy uses radiolabeled monoclonal antibodies to locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tu...
What is the current status of trial NCT00058370?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2003-02. Estimated completion is 2019-06.
What conditions does trial NCT00058370 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00058370?
The interventions under investigation include: cisplatin (DRUG), adjuvant therapy (PROCEDURE), vincristine sulfate (DRUG), lomustine (DRUG), iodine I 131 monoclonal antibody 3F8 (RADIATION).
Who is sponsoring clinical trial NCT00058370?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00058370 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00058370's enrollment target sits among peer trials
6 44th of 45 higher than 1 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia